Journal
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
Volume 315, Issue 6, Pages F1519-F1525Publisher
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajprenal.00211.2018
Keywords
albuminuria; anti-inflammatory therapy; diabetes; end-stage renal disease
Categories
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases [5UM1-DK-100846-03, 1U54-DK-083912, U2C-DK-114886]
- National Center for Advancing Translational Sciences Grant [4UL1TR000423-10/WESC8883]
- Janssen Research and Development Grant
Ask authors/readers for more resources
Diabetic kidney disease (DKD), one of the most common and severe microvascular complications of diabetes, is the leading cause of chronic kidney disease and end-stage kidney disease worldwide. Since the development of renin-angiotensin system inhibition nearly three decades ago, no new therapeutic agents have received regulatory approval for treatment of DKD. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of newer antihyperglycemic agents, have shown promise for prevention of DKD onset and progression. This perspective summarizes clinical and experimental observations to give insight into biological mechanisms beyond glycemic control, such as natriuresis and anti-inflammatory actions, for preservation of kidney function in patients with diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available